Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander filed a Schedule 13G Amendment No. 1 with the SEC on October 27, 2026, disclosing a beneficial ownership position in Karyopharm Therapeutics Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Each reporting person disclosed 42,888 shares of Karyopharm Therapeutics Inc. common stock, par value $0.0001 per share.
  • Percent of class: The 42,888 shares represent 0.2% of the class, according to the filing.
  • No sole voting or dispositive power: All four reporting persons reported 0 shares with sole voting power and 0 shares with sole dispositive power.
  • Shared voting and dispositive power: All 42,888 shares are held with shared voting power and shared dispositive power by each reporting person.
  • Triggering event date: The date of event requiring the filing is stated as September 30, 2026.
  • Filing date: The statement was signed and dated October 27, 2026, by Gil Raviv as Global General Counsel for the three entities, and by Israel A. Englander personally.

Millennium Entities and Englander Disclose 0.2% Stake in Karyopharm Therapeutics

According to the filing, four reporting persons - Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander - jointly submitted Schedule 13G Amendment No. 1 in connection with their holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). The issuer's common stock carries a par value of $0.0001 per share and is identified by CUSIP number 48576U205. The filing states that the triggering event date was September 30, 2026.

The filing discloses that all 42,888 shares are attributed to each reporting person on a shared basis, with no sole voting or dispositive power reported by any of them. The filing states that "the securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC." The filing further notes that "the foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities."

The filing confirms this is a passive position, consistent with ownership of 5 percent or less of the class. Item 10 of the filing includes a certification that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." All three entities are organized under Delaware law and share a principal business address at 399 Park Avenue, New York, New York 10022. Karyopharm Therapeutics is headquartered at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459, according to the filing.

What Was Disclosed

Four Millennium-affiliated reporting persons filed a Schedule 13G amendment disclosing shared beneficial ownership of 42,888 shares of Karyopharm Therapeutics common stock, representing 0.2% of the class, as of September 30, 2026.